<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04236687</url>
  </required_header>
  <id_info>
    <org_study_id>HBP01</org_study_id>
    <nct_id>NCT04236687</nct_id>
  </id_info>
  <brief_title>Prostate Artery Embolization Compared to Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia</brief_title>
  <official_title>Prospective, Controlled Investigation of Prostate Artery Embolization Compared to Holmium Laser Enucleation of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate improvement of symptoms from benign prostatic
      hyperplasia (BPH) as assessed by the International Prostate Symptom Score (IPSS) for prostate
      artery embolization (PAE) with microspheres (Embozene™, 400µm) compared to conventional
      Holmium laser enucleation of the prostate (HoLEP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized controlled study that collects data of patients with benign
      prostatic hyperplasia that are treated with prostatic artery embolization (PAE) or with
      Holmium laser enucleation of the prostate (HoLEP). For PAE a catheter is placed in the
      prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected
      through the catheter into these small arteries which nourish the prostate. The injected
      microspheres will slow the blood flow to the prostate. For HoLEP a Holmium laser will be used
      to enucleate the prostatic hyperplasia trough the urethra. Clinical follow-up include
      clinical visit after 1, 6 and 12 months. Acute as well as long term complications will be
      recorded. The patients fill in the questionnaires for urologic disease. Urodynamic
      examination will record functional outcome.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of symptoms assessed by International Prostate Symptom Score (IPSS)</measure>
    <time_frame>Baseline to 6 months after procedure</time_frame>
    <description>Change in prostatic symptoms using the International Prostate Symptom Score (IPSS). IPSS score goes from 0 to 35. Higher values mean worse outcome (prostate symptons)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum urinary flow</measure>
    <time_frame>Baseline to 6 months after procedure</time_frame>
    <description>Maximum urinary flow rate (Qmax). Evaluated in milliliter per seconds (mL/s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-void residual urinary volume</measure>
    <time_frame>Baseline to 6 months after procedure</time_frame>
    <description>Post-void residual urinary volume (PVR). Post-void urinary volume: evaluated in milliliters (mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate specific antigen (PSA)</measure>
    <time_frame>Baseline to 6 months after procedure</time_frame>
    <description>Determination in plasma of the prostate specific antigen (PSA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure related adverse events</measure>
    <time_frame>Baseline to 6 months after procedure</time_frame>
    <description>Evaluation of Procedure related adverse events assessed by Clavien-Dindo modified score. Clavien Dindo modified score: the score goes from 1 to 5. Higher values mean worse outcome (surgical complications)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure related effects on sexual function</measure>
    <time_frame>Baseline to 6 months after procedure</time_frame>
    <description>Changes in sexual function assessed by International Index of Erectile Function (IIEF) score. IIEF: the score goes from 6 to 75. Lower values mean worse outcome (overall male sexual function).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure related effects on urinary continence</measure>
    <time_frame>Baseline to 6 months after procedure</time_frame>
    <description>Changes in urinary continence assessed by the International Consultation on Continence Questionnaire Short Form (ICIQ-SF). ICIQ-SF: score goes from 0 to 21. Higher values mean worse outcome (urinary continence)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Holmium laser enucleation of the prostate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Holmium laser will be used to enucleate the prostatic hyperplasia trough the urethra</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artery embolization of the prostate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate. The injected microspheres will slow the blood flow to the prostate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Holmium laser enucleation of the prostate</intervention_name>
    <description>Holmium laser will be used to enucleate the prostatic hyperplasia trough the urethra</description>
    <arm_group_label>Holmium laser enucleation of the prostate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Artery embolization of the prostate</intervention_name>
    <description>A catheter is placed in the prostate artery, a fluid containing thousands of tiny particles (microspheres) is injected through the catheter into these small arteries which nourish the prostate</description>
    <arm_group_label>Artery embolization of the prostate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients evaluated in the urology department and candidates to surgical treatment

          -  Age &gt; 45 years

          -  IPSS ≥ 10

          -  Maximum urinary flow &lt; 12 milliliters (mL)/second (s)

          -  Post-void residual urinary volume &lt; 300mL

          -  Prostatic volume between 20mL and 250mL assessed by ultrasound

          -  Signed informed consent

        Exclusion Criteria:

          -  PSA &gt; 10 (if not negative prostate biopsy)

          -  Life expectancy below 1 year

          -  Renal insufficiency defined as Glomerular Filtration Rate &lt; 30 ml/min/1,73m2

          -  Known severe reactions to iodine-based contrast or gadolinium-based contrast

          -  CT examination reveals no access to the prostate arteries.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Agreda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fernando Agreda, MD</last_name>
    <phone>+34934893000</phone>
    <email>fagreda.germanstrias@gencat.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaume Sampere, MD</last_name>
    <phone>+34934893000</phone>
    <email>jsampere.germanstrias@gencat.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Fernando Agreda, MD</last_name>
      <phone>+34934893000</phone>
      <email>fagreda.germanstrias@gencat.cat</email>
    </contact>
    <contact_backup>
      <last_name>Jaume Sanpere, MD</last_name>
      <phone>+34934893000</phone>
      <email>fagreda.germanstrias@gencat.cat</email>
    </contact_backup>
    <investigator>
      <last_name>Fernando Agreda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaume Sanpere, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerardo Tovar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Salvador, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauro Bernardello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

